肿瘤细胞治疗研究
ALL SOURCES
CAR+ extracellular vesicles predict ICANS in patients with B cell lymphomas treated with CD19-directed CAR T cells.
一项纳入 100 例接受已获批 CD19.CAR T 细胞产品输注的 B 细胞淋巴瘤患者的前瞻性队列，评估了血浆 CAR+EVs 作为体内 CD19.CAR T 细胞活化生物标志物的价值。
Gp350-anchored extracellular vesicles: promising vehicles for delivering therapeutic drugs of B cell malignancies.
我们的发现提示，载药 RBC-EVs/gp350 Etp 或可用于 CD21+ B 细胞恶性肿瘤的治疗。
Advancements in Personalized CAR-T Therapy: Comprehensive Overview of Biomarkers and Therapeutic Targets in Hematological Malignancies.
CAR-T 细胞疗法是一种使用自体或异体T细胞的新型抗癌疗法。
The multifaceted roles of extracellular vesicles for therapeutic intervention with non-Hodgkin lymphoma.
细胞外囊泡（EVs）以多种方式参与癌症的发生发展。
Peripheral blood cellular profile at pre-lymphodepletion is associated with CD19-targeted CAR-T cell-associated neurotoxicity.
我们的数据支持 CAR-T 治疗前全身性炎症与 ICANS 相关的观点。
Extracellular Vesicles Expressing CD19 Antigen Improve Expansion and Efficacy of CD19-Targeted CAR-T Cells.
我们的研究结果表明，表达抗原的EV可作为增强剂，在体外和体内提高CAR-T细胞的疗效。
Harnessing the power of exosomes in leukemia: from molecular messengers to clinical applications.
外泌体，即纳米级细胞外囊泡（30-150 nm），已成为白血病发病机制中的关键介质，从根本上改变了我们对这一疾病及治疗策略的认识。
Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy.
CAR 细胞疗法已显著推进了多种血液系统恶性肿瘤的个体化治疗。
Lymphoma-derived extracellular vesicles inhibit CAR T cell function.
靶向 CD19 的 CAR T 细胞疗法在治疗复发/难治性 B 细胞淋巴瘤中显示出显著疗效。
Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function of CD19-specific CAR T-cells via TGF-β signaling.
富含免疫抑制分子的肿瘤来源外泌体（TEXs）主要驱动 T 细胞功能障碍并损害抗肿瘤免疫。
共 10 条
MEMBER ACCOUNT
登录成功会直接打开下一页。
